Tomorrow Is Not Likely To Be Same For Supernus Pharmaceuticals Inc (SUPN)

Supernus Pharmaceuticals Inc (SUPN) concluded trading on Thursday at a closing price of $34.11, with 0.49 million shares of worth about $16.75 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 19.35% during that period and on March 28, 2024 the price saw a gain of about 1.10%. Currently the company’s common shares owned by public are about 54.72M shares, out of which, 52.39M shares are available for trading.

Stock saw a price change of -3.01% in past 5 days and over the past one month there was a price change of 9.75%. Year-to-date (YTD), SUPN shares are showing a performance of 17.86% which decreased to -6.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $21.99 but also hit the highest price of $39.09 during that period. The average intraday trading volume for Supernus Pharmaceuticals Inc shares is 382.58K. The stock is currently trading 4.32% above its 20-day simple moving average (SMA20), while that difference is up 13.50% for SMA50 and it goes to 17.16% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Supernus Pharmaceuticals Inc (NASDAQ: SUPN) currently have 54.72M outstanding shares and institutions hold larger chunk of about 106.53% of that.

The stock has a current market capitalization of $1.87B and its 3Y-monthly beta is at 0.99. It has posted earnings per share of -$0.00 in the same period. It has Quick Ratio of 1.43 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SUPN, volatility over the week remained 4.35% while standing at 4.22% over the month.

Analysts are in expectations that Supernus Pharmaceuticals Inc (SUPN) stock would likely to be making an EPS of $0.38 in the current quarter, while forecast for next quarter EPS is $0.37 and it is $1.95 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.29 which is $0.48 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.7 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -30.39% while it is estimated to increase by 18.94% in next year. EPS is likely to grow at an annualized rate of 1.69% for next 5-years, compared to annual growth of -59.02% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on January 03, 2023 offering a Buy rating for the stock and assigned a target price range of between $44 and $45 to it. Coverage by Jefferies stated Supernus Pharmaceuticals Inc (SUPN) stock as a Buy in their note to investors on December 01, 2021, suggesting a price target of $44 for the stock. On April 13, 2021, Jefferies Upgrade their recommendations, while on June 16, 2020, Piper Sandler Upgrade their ratings for the stock with a price target of $31. Stock get a Hold rating from Jefferies on June 15, 2020.

Most Popular

Related Posts